Newron announced the initiation of a new clinical trial with Evenamide in patients with schizophrenia

BY      |     January 9, 2020

Newron Pharmaceuticals, a biopharmaceutical company developing therapies for patients with neurological diseases, announced the initiation of the short-term explanatory trial with Evenamide to address previously announced potential safety issues raised by the FDA.

Evenamide is a voltage-gated sodium channel blocker, developed by Newron as an add-on therapy for the treatment of schizophrenia. Evanimide (when administered together with some common atypical antipsychotics) has been reported to significantly improve symptoms of psychosis in patients with chronic schizophrenia, in a Phase II study.

The successful completion of the announced explanatory study is a prerequisite for Newron to start its Phase III program. The results are expected by Q3-Q4 2020.

Read more about Newron Pharmaceuticals here.

Image by Colin Behrens from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.